Assessing the Prognostic Link Between Inflammation and Cardiovascular Disease: Can C - Reactive Protein Emerge as an Independent Risk Marker?
Cardiovascular disease (CVD) has emerged as a major disease in the adult population. Current protocols for the prevention of myocardial infarction, stroke and death from other CVD have concentrated on modifying preventable measures such as smoking, dyslipidemia, hypertension, diabetes, and physical activity.
The use of statins shows a proportional reduction in vascular risk with an absolute decrease in LDL cholesterol. Clinical evidence suggests that the inflammatory process is an important contributor to atherogenesis and instability of the plaque. Elevated levels of the inflammation marker C - Reactive Protein (CRP) show a significant link between first cardiovascular event. In addition,
statins reduce cholesterol and CRP and contribute to the beneficial effects of these medications.
This epidemiological study will determine the frequency of testing for CRP at a tertiary care health center in Saudi Arabia, and correlate the data to statin use and the first incidence of CVD. The methodology is to review the literature and collate the prevalence of underlying atherosclerosis among patience receiving statin treatment and those with elevated CRP but normal LDL levels. The significance of this study is to emphasize the role of inflammation as equally as LDL in heart disease manifestations, and determine whether CRP should be a mandatory test for patients with heart diseases.